Depot risperidone, hyperprolactinaemia and prolactin-associated side-effects

Psychiatric Bulletin

Volumn 32, Issue 9, 2008, Pages 358-359

  McIlhinney, Selwyn ^a   Smith, Michael ^b  

^a WHANGAREI HOSPITAL   (New Zealand)

^b Dykebar Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROLACTIN; RISPERIDONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; LETTER; LIBIDO DISORDER; MENSTRUATION DISORDER; OSTEOPOROSIS; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; SLOW RELEASE FORMULATION; SYMPTOM; TREATMENT DURATION;

EID: 52049100613     PISSN: 09556036     EISSN: None     Source Type: Journal    
DOI: 10.1192/pb.32.9.358b     Document Type: Letter

References (3)

1. BUSHE, C. & SHAW, M. (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology, 21, 768-773.
2. MAGUIRE, G. A. (2002) Prolactin elevation with antipsychotic medicationi mechanisms of action and dinical consequences. Joumal of Clinical Psychiatry, 63 (suppl. 4), 56-62.
3. NAIDOO, U., GOFF, D. C. & KLIBANSKI, A. (2003) Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology, 28, 97-108.